Bactiguard appoints Carin Jakobson as new CFO
Bactiguard Holding AB (publ) has appointed Carin Jakobson, who has many years of experience as CFO of listed companies and a background in the medtech and pharmaceutical industry, as Chief Financial Officer. Carin Jakobson, who is currently CFO of the Rolling Optics Group, will take up her new position at Bactiguard in June 2022 and report to the CEO.
“Bactiguard is in an expansive growth phase, and we look forward to welcoming Carin to us. She has extensive experience as CFO in several publicly listed companies with focus on growth in various industries. I am very pleased with the recruitment of Carin, who will make a valuable contribution to Bactiguard and look forward to working closely with her in the management team”, says Anders Göransson, CEO of Bactiguard.
"I am really looking forward to joining Bactiguard and working with the team to continue developing the company for stronger growth and profitability and thus increased shareholder value", says Carin Jakobson.
Carin Jacobson is 47 years old and holds a master's degree in business administration from Linnéuniversitetet (Linnaeus University). Since 2018, she has been CFO of the Rolling Optics Group. Prior to that, she served as CFO of Stille AB, Sivers IMA, and Annexin Pharmaceuticals AB.
Carin Jakobson will take up her position in June and replaces Gabriella Björknert Caracciolo.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2022-03-21, at 17.30.
For more information, please contact:
Anders Göransson, CEO, phone +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com
